Hambleton Julie 4
4 · SpringWorks Therapeutics, Inc. · Filed Jun 5, 2024
Insider Transaction Report
Form 4
Hambleton Julie
Director
Transactions
- Sale
Common Stock
2024-06-03$39.41/sh−2,946$116,111→ 5,797 total - Sale
Common Stock
2024-06-03$41.49/sh−931$38,629→ 4,115 total - Sale
Common Stock
2024-06-03$40.57/sh−751$30,465→ 5,046 total - Sale
Common Stock
2024-06-03$42.09/sh−20$842→ 4,095 total
Footnotes (5)
- [F1]The sales reported on this Form 4 were effected pursuant to a trading plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, adopted on March 1, 2024.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.02 to $40.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.02 to $40.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.02 to $42.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.06 to $42.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.